TW201625545A - 取代唑化合物及糖尿病治療藥 - Google Patents

取代唑化合物及糖尿病治療藥 Download PDF

Info

Publication number
TW201625545A
TW201625545A TW104115166A TW104115166A TW201625545A TW 201625545 A TW201625545 A TW 201625545A TW 104115166 A TW104115166 A TW 104115166A TW 104115166 A TW104115166 A TW 104115166A TW 201625545 A TW201625545 A TW 201625545A
Authority
TW
Taiwan
Prior art keywords
group
compound
ring
mmol
substituted
Prior art date
Application number
TW104115166A
Other languages
English (en)
Chinese (zh)
Inventor
新谷友輔
丹羽雅俊
門馬壮一
石山聖志
繁田幸宏
神山利彥
嶋澤嘉伸
岡田和朗
Original Assignee
日產化學工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日產化學工業股份有限公司 filed Critical 日產化學工業股份有限公司
Publication of TW201625545A publication Critical patent/TW201625545A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
TW104115166A 2014-05-09 2015-05-11 取代唑化合物及糖尿病治療藥 TW201625545A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014098007A JP2017119628A (ja) 2014-05-09 2014-05-09 置換アゾール化合物及び糖尿病治療薬

Publications (1)

Publication Number Publication Date
TW201625545A true TW201625545A (zh) 2016-07-16

Family

ID=54392622

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104115166A TW201625545A (zh) 2014-05-09 2015-05-11 取代唑化合物及糖尿病治療藥

Country Status (3)

Country Link
JP (1) JP2017119628A (fr)
TW (1) TW201625545A (fr)
WO (1) WO2015170775A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397311A (zh) * 2016-08-31 2017-02-15 安徽省鸿鑫生物科技有限公司 一种1‑[5‑(苯基甲氧基)‑2‑吡啶]‑乙酮的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019068613A1 (fr) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh Nouveaux composés de [1,6]naphthyridine et dérivés utilisés en tant qu'inhibiteurs de cdk8/cdk19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374860A1 (en) * 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
KR20100033419A (ko) * 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
BRPI0909469A2 (pt) * 2008-03-31 2015-12-29 Metabolex Inc compostos de oximetileno de arila e usos dos mesmos
GEP20135907B (en) * 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
AU2010279964B2 (en) * 2009-08-05 2016-02-11 Daiichi Sankyo Company, Limited Amide derivative
SI2628733T1 (sl) * 2010-10-14 2015-10-30 Daiichi Sankyo Company, Limited Derivati acilbenzena
BR112013011865A2 (pt) * 2010-11-23 2016-08-23 Pfizer moduladores de gpr119
JP5973440B2 (ja) * 2011-07-29 2016-08-23 第一三共株式会社 Ｎ−ヘテロ環置換アミド誘導体
MX2014008790A (es) * 2012-01-18 2014-10-13 Daiichi Sankyo Co Ltd Derivado de fenilazol sustituido.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397311A (zh) * 2016-08-31 2017-02-15 安徽省鸿鑫生物科技有限公司 一种1‑[5‑(苯基甲氧基)‑2‑吡啶]‑乙酮的制备方法

Also Published As

Publication number Publication date
WO2015170775A1 (fr) 2015-11-12
JP2017119628A (ja) 2017-07-06

Similar Documents

Publication Publication Date Title
JP7088983B2 (ja) キナーゼ阻害剤としてのビアリールアミド化合物
JP7017521B2 (ja) アクチビン受容体様キナーゼの阻害剤
RU2685234C1 (ru) Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
JP7440101B2 (ja) キナーゼ阻害剤としてのヘテロ環式化合物、ヘテロ環式化合物を含む組成物、及びそれらを使用する方法
JP6387086B2 (ja) 新規ソマトスタチン受容体亜型４（ｓｓｔｒ４）作動薬
TWI382026B (zh) 經取代的雜芳基物
CN111892577A (zh) 用于雄激素受体靶向降解的化合物和方法
TW201706263A (zh) 化合物
JP2021193099A (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
RU2684637C1 (ru) Производные тетрагидробензимидазола в качестве модуляторов активности tnf
TW201831481A (zh) 作為Ｒｈｏ激酶抑制劑之酪胺酸醯胺衍生物
CN112424167A (zh) 化学化合物
TW201444849A (zh) 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
WO2019101086A1 (fr) Inhibiteur de ssao/vap-1 halo-allylamine et son utilisation
AU2014315109A1 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors
EA038173B1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
RU2684635C1 (ru) Производные тетрагидроимидазопиридина в качестве модуляторов активновти tnf
EA033679B1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
TW202115054A (zh) 經取代的雜芳族吡唑并－吡啶及其作為ｇｌｕｎ２ｂ受體調節劑的用途
TW201708217A (zh) 氮雜苯并咪唑類及其作為ａｍｐａ受體調控劑之用途
EP2976341A1 (fr) Cyanoéthylpyrazolo pyridones acycliques en tant qu'inhibiteurs de janus kinase
JP2014159376A (ja) アザスピロアルカン化合物
CN113490668A (zh) 用于治疗与apj受体活性有关的疾病的化合物和组合物
CN111747954B (zh) 吡嗪化合物和其用途